DATA GRAPHICS | Deals
AZ in AI discovery deal with China’s CSPC: Deals Report
Plus: Biontech acquiring fellow German mRNA play Curevac, Supernus buying Sage, and more
June 17, 2025 1:19 AM UTC
Astrazeneca became the latest big pharma to announce a discovery deal with a Chinese company, paying $110 million up front in a partnership with CSPC last week.
CSPC Pharmaceuticals Group Ltd. (HKEX:1093) will use its AI platform to discover oral compounds for multiple chronic diseases, including at least one small molecule in immunology. The company is eligible for a total of $5.3 billion from Astrazeneca plc (LSE:AZN: NYSE:AZN) under the deal, including the upfront money, $1.6 billion in development milestones and $3.6 billion in sales milestones. The European pharma will receive options to advance resulting compounds. ...